Multiplex imaging and analysis using the Enable Cloud Platform to predict TNF inhibitor response in ulcerative colitis patients

Ulcerative colitis (UC) is a chronic-relapsing inflammatory bowel disease (IBD). Patients with UC have a 1.5 times higher risk for colorectal cancer compared to healthy individuals. TNF inhibitors such as infliximab and adalimumab are frontline targeted therapies for UC but 13-40% UC patients are non-responsive to TNFi therapy and up to 46% show loss of resistance. Since these drugs are immunosuppressive, they can lead to opportunistic infections, driving up the cost following UC treatment, especially in non-responders. In order to implement individualized therapy to patients effectively, it is critical to understand the differences between individual patients that could affect responses to TNF therapy.